Table 1 Demographic features of 223 OMG patients
Variables | n (%) |
|---|---|
Disease duration (y), median (IQR) | 4 (2–6) |
Gender | (N = 223) |
Male | 116 (52.0) |
Female | 107 (48.0) |
Age of onset | (N = 223) |
< 20 y | 110 (49.3) |
≥ 20 y | 113 (50.7) |
Initial symptoms | (N = 223) |
Unilateral ptosis | 110 (49.3) |
Bilateral ptosis | 40 (17.9) |
Diplopia | 10 (4.5) |
Unilateral ptosis with diplopia | 42 (18.8) |
Bilateral ptosis with diplopia | 21 (9.4) |
Neostigmine test | (N = 171) |
Positive | 163 (95.3) |
Negative | 8(4.7) |
Positive rate of RNS test | |
Facial nerve | 25/84 (29.8) |
Axillary nerve | 18/76 (23.7) |
Ulnar nerve | 2/74 (2.7) |
Thyroid abnormality | (N = 102) |
Hyperthyroidism | 9 (8.8) |
Subclinical hyperthyroidism | 4 (3.9) |
Hypothyroidism | 2 (2.0) |
Subclinical hypothyroidism | 2 (2.0) |
Thymus abnormality | (N = 174) |
Thymoma | 25 (14.4) |
Thymic hyperplasia | 7 (4.0) |
Non-degraded thymus | 7 (4.0) |
Immunosuppressants | (N = 223) |
Steroids | 159 (71.3%) |
Azathioprine | 8 (3.6%) |
Steroids + azathioprine | 53 (23.8%) |
Steroids + cyclosporine A | 2 (0.9%) |
Steroids + IVIg | 1 (0.4%) |